Sunbelt Securities’s Coherus Oncology CHRS Stock Holding History

Sunbelt Securities’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27	Hold	16	–	–	﹤0.01%	2845
2025 Q4	$23	Buy	+16	New	+$23	﹤0.01%	2722

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Sunbelt Securities's CHRS Position: Q1 2026 in Review

Sunbelt Securities held its Coherus Oncology (CHRS) position steady in Q1 2026 at 16 shares worth $27. The position accounts for ﹤0.01% of the portfolio, ranked #2845.

Sunbelt Securities first reported a position in CHRS in Q4 2025 and has held it in 2 quarters since. 158 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

Sunbelt Securities held 16 shares of Coherus Oncology worth $27 as of Q1 2026.
Sunbelt Securities left its Coherus Oncology share count unchanged in Q1 2026.
Coherus Oncology made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #2845 holding.
Sunbelt Securities first reported a position in Coherus Oncology in Q4 2025 and has held it in 2 quarters since.
158 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.